These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30277463)

  • 21. Drug-Coated Balloon Versus Plain Balloon Angioplasty for the Treatment of Femoropopliteal Artery Disease: An Updated Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Giacoppo D; Cassese S; Harada Y; Colleran R; Michel J; Fusaro M; Kastrati A; Byrne RA
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1731-42. PubMed ID: 27539695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of the paclitaxel-coated Luminor® balloon catheter versus an uncoated balloon catheter in superficial femoral and popliteal arteries in preventing vessel restenosis or reocclusion: study protocol for a randomized controlled trial.
    Teichgräber U; Aschenbach R; Scheinert D; Zeller T; Brechtel K; Thieme M; Blessing E; Treitl M; Lichtenberg M; von Flotow P; Vogel B; Werk M; Riambau V; Wienke A; Lehmann T; Sixt S
    Trials; 2016 Oct; 17(1):528. PubMed ID: 27793175
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Two-year Review on Mortality and Morbidity after Femoropopliteal Drug-coated Balloon Angioplasty in the Randomized EffPac Trial.
    Teichgräber U; Lehmann T; Aschenbach R; Thieme M; Zeller T; Beschorner U; Scheinert D
    Radiology; 2020 Sep; 296(3):638-640. PubMed ID: 32692299
    [No Abstract]   [Full Text] [Related]  

  • 24. Drug-coated balloon treatment of complex femoropopliteal disease yields favorable and durable outcomes at 5 years.
    Winscott JG; Hillegass WB
    Catheter Cardiovasc Interv; 2022 Dec; 100(7):1284-1285. PubMed ID: 36521184
    [No Abstract]   [Full Text] [Related]  

  • 25. Low-Dose Paclitaxel-Coated Balloons for Femoropopliteal Disease: Days of Future Past?
    Biondi-Zoccai G; Spadafora L; Giordano A
    JACC Cardiovasc Interv; 2023 Nov; 16(21):2666-2669. PubMed ID: 37804289
    [No Abstract]   [Full Text] [Related]  

  • 26. First-in-man experience of self-expanding nitinol stents combined with drug-coated balloon in the treatment of femoropopliteal occlusive disease.
    Mwipatayi BP; Perera K; Daneshmand A; Daniel R; Wong J; Thomas SD; Burrows SA
    Vascular; 2018 Feb; 26(1):3-11. PubMed ID: 28436316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Ott I; Ndrepepa G; Nerad M; Kastrati A; Fusaro M
    Circ Cardiovasc Interv; 2012 Aug; 5(4):582-9. PubMed ID: 22851526
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
    Xu Y; Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2347-2353. PubMed ID: 30448170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study.
    Schroeder H; Meyer DR; Lux B; Ruecker F; Martorana M; Duda S
    Catheter Cardiovasc Interv; 2015 Aug; 86(2):278-86. PubMed ID: 25708850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Efficacy of balloon catheters with antiproliferative cover in patients with impairment of arteries of femoral-popliteal segment].
    Pityk AI
    Klin Khir; 2015 Feb; (2):49-51. PubMed ID: 25985697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IN.PACT™ Admiral™ drug-coated balloon: Durable, consistent and safe treatment for femoropopliteal peripheral artery disease.
    Peterson S; Hasenbank M; Silvestro C; Raina S
    Adv Drug Deliv Rev; 2017 Mar; 112():69-77. PubMed ID: 27771367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Standard balloon angioplasty versus angioplasty with paclitaxel-eluting balloons for femoropopliteal artery stenosis.
    Ju MH; Rodríguez HE
    J Cardiovasc Surg (Torino); 2012 Aug; 53(4):459-63. PubMed ID: 22854525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Commentary: treatment of femoropopliteal in-stent restenosis for patients with diabetes: do we have an answer to the DEBATE?
    Armstrong EJ; Laird JR
    J Endovasc Ther; 2014 Feb; 21(1):9-11. PubMed ID: 24502478
    [No Abstract]   [Full Text] [Related]  

  • 36. Commentary: how do we deal with dissection after angioplasty?
    Fanelli F; Cannavale A; Gazzetti M; D'Adamo A
    J Endovasc Ther; 2013 Dec; 20(6):801-4. PubMed ID: 24325696
    [No Abstract]   [Full Text] [Related]  

  • 37. Directional Atherectomy With Antirestenotic Therapy vs Drug-Coated Balloon Angioplasty Alone for Isolated Popliteal Artery Lesions.
    Stavroulakis K; Schwindt A; Torsello G; Stachmann A; Hericks C; Bosiers MJ; Beropoulis E; Stahlhoff S; Bisdas T
    J Endovasc Ther; 2017 Apr; 24(2):181-188. PubMed ID: 28008792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial.
    Scheinert D; Schulte KL; Zeller T; Lammer J; Tepe G
    J Endovasc Ther; 2015 Feb; 22(1):14-21. PubMed ID: 25775674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk Factors for Restenosis after Drug-coated Balloon Angioplasty for Complex Femoropopliteal Arterial Occlusive Disease.
    Roh JW; Ko YG; Ahn CM; Hong SJ; Shin DH; Kim JS; Kim BK; Choi D; Hong MK; Jang Y
    Ann Vasc Surg; 2019 Feb; 55():45-54. PubMed ID: 30118857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous revascularization for peripheral arterial disease: paclitaxel saves the day.
    Mahmud E
    JACC Cardiovasc Interv; 2013 Mar; 6(3):290-2. PubMed ID: 23517841
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.